Phibro(US:PAHC)2025-05-08 15:18Financial Performance - Q3 FY2025 - Consolidated net sales increased to $347.8 million, compared to $263.2 million in Q3 FY24[12] - Consolidated adjusted EBITDA increased to $45 million, an 85% increase compared to $29.7 million in Q3 FY24[12] - Animal Health sales increased by 42% to $258.4 million[10, 16] - Animal Health adjusted EBITDA increased by 73% to $63.1 million[10, 16] - Mineral Nutrition net sales increased by 4% to $66.8 million[10, 20] - Performance Products net sales increased by 28% to $22.7 million[10, 21] FY2025 Guidance - Net sales are projected to be between $1.260 billion and $1.290 billion[11] - Adjusted EBITDA is projected to be between $177 million and $183 million[11] - Adjusted EPS is projected to be between $1.96 and $2.09[11] Capitalization - Free cash flow was $49 million for the trailing twelve months[25] - The company has a gross leverage ratio of 3.0x, with $734 million in total debt[25] - The company has a net leverage ratio of 2.7x, with $664 million in net debt[25]